8 March 2018 EMA/135395/2018 Human Medicines Evaluation Division

List of nationally authorised medicinal products

Active substance: theophylline

Procedure No.: PSUSA/00002921/201706

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5525 Send a question via our website www.ema.europa.eu/contact

An agency of the European Union

© European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged.

Product Name (in authorisation country)

MRP/DCP Authorisation number

National Authorisation Number

MAH of product in the member state

Member State where product is authorised

DILATRANE 1 POUR

not available

V07675-3400930317808

SOCIETE D'ETUDES ET DE

FR

CENT, sirop

RECHERCHES PHARMACEUTIQUES (SERP)

DILATRANE 100 mg,

not available

V07674-3400930317747

SOCIETE D'ETUDES ET DE

gélule à libération

RECHERCHES

prolongée

PHARMACEUTIQUES (SERP)

Theophyllin STADA® 400

FR

not available

31200.00.00

STADAPHARM GMBH

DE

not available

PL 11648/0080

MERCK SERONO LTD.

UK

not available

PL 11648/0081

MERCK SERONO LTD.

UK

not available

PL 11648/0079

MERCK SERONO LTD.

UK

not available

2707.00.00

SANOFI-AVENTIS

DE

mg Hartkapseln, retardiert Slo-Phyllin 125 mg Capsules Slo-Phyllin 250 mg Capsules Slo-Phyllin 60 mg Capsules SOLOSIN RETARD

DEUTSCHLAND GMBH SOLOSIN RETARD

not available

2707.00.00

SANOFI-AVENTIS

DE

DEUTSCHLAND GMBH SOLOSIN

not available

2707.00.01

INFUSIONSLÖSUNGSKON

SANOFI-AVENTIS

DE

DEUTSCHLAND GMBH

ZENTRAT SOLOSIN

not available

INFUSIONSLÖSUNGSKON

2707.00.01

SANOFI-AVENTIS

DE

DEUTSCHLAND GMBH

ZENTRAT List of nationally authorised medicinal products EMA/135395/2018

Page 2/22

Product Name (in authorisation country)

MRP/DCP Authorisation number

National Authorisation Number

MAH of product in the member state

Member State where product is authorised

SOLOSIN RETARD MITE

not available

2707.01.00

SANOFI-AVENTIS

DE

DEUTSCHLAND GMBH SOLOSIN RETARD

not available

2707.00.00

SANOFI-AVENTIS

DE

DEUTSCHLAND GMBH SOLOSIN RETARD

not available

2707.00.00

SANOFI-AVENTIS

DE

DEUTSCHLAND GMBH SOLOSIN RETARD

not available

2707.00.00

SANOFI-AVENTIS

DE

DEUTSCHLAND GMBH SOLOSIN

not available

2707.00.01

INFUSIONSLÖSUNGSKON

SANOFI-AVENTIS

DE

DEUTSCHLAND GMBH

ZENTRAT SOLOSIN RETARD MITE

not available

2707.01.00

SANOFI-AVENTIS

DE

DEUTSCHLAND GMBH SOLOSIN RETARD MITE

not available

2707.01.00

SANOFI-AVENTIS

DE

DEUTSCHLAND GMBH SOLOSIN RETARD MITE

not available

2707.01.00

SANOFI-AVENTIS

DE

DEUTSCHLAND GMBH SOLOSIN RETARD MITE

not available

2707.01.00

SANOFI-AVENTIS

DE

DEUTSCHLAND GMBH

List of nationally authorised medicinal products EMA/135395/2018

Page 3/22

Product Name (in authorisation country)

MRP/DCP Authorisation number

National Authorisation Number

MAH of product in the member state

Member State where product is authorised

Theo-Dur 200mg

not available

6607

BIOPHAUSIA AB

NO

not available

6608

BIOPHAUSIA AB

NO

not available

1.891

TAKEDA GMBH (KONSTANZ)

ES

not available

025267016

RECORDATI INDUSTRIA

IT

depottablett Theo-Dur 300mg depottablett Eufilina Venosa 200 mg solución inyectable Theo-dur 300 mg compresse a rilascio

CHIMICA E FARMACEUTICA

prolungato Theo-dur 200 mg

S.P.A. not available

025267028

RECORDATI INDUSTRIA

compresse a rilascio

CHIMICA E FARMACEUTICA

prolungato

S.P.A.

Nuelin Depot 175 mg

IT

not available

8131

MEDA OY

FI

not available

8792

MEDA OY

FI

not available

8132

MEDA OY

FI

not available

56160

MEDA PHARMA S.A.U.

ES

depottabletter Nuelin Depot 350 mg depottabletter Nuelin Depot 250 mg depottabletter Theolair 175 mg, comprimidos de liberación prolongada

List of nationally authorised medicinal products EMA/135395/2018

Page 4/22

Product Name (in authorisation country)

MRP/DCP Authorisation number

National Authorisation Number

MAH of product in the member state

Member State where product is authorised

Theolair 250 mg,

not available

56161

MEDA PHARMA S.A.U.

ES

not available

025730019

MEDA PHARMA S.P.A.

IT

not available

025730021

MEDA PHARMA S.P.A.

IT

not available

6590

MEDA AS

NO

not available

6600

MEDA AS

NO

not available

8131

MEDA OY

FI

not available

8132

MEDA OY

FI

not available

8792

MEDA OY

FI

not available

RVG 09107

MEDA PHARMA B.V.

NL

comprimidos de liberación prolongada THEOLAIR compresse a rilascio prolungato THEOLAIR compresse a rilascio prolungato Nuelin Depot 250 mg depottablett Nuelin Depot 350 mg depottablett Nuelin Depot 175 mg depottabletit Nuelin Depot 250 mg depottabletti Nuelin Depot 350 mg depottabletti Theolair Retard 175, tabletten met gereguleerde afgifte 175 mg

List of nationally authorised medicinal products EMA/135395/2018

Page 5/22

Product Name (in authorisation country)

MRP/DCP Authorisation number

National Authorisation Number

MAH of product in the member state

Member State where product is authorised

Theolair Retard 250,

not available

RVG 08391

MEDA PHARMA B.V.

NL

not available

RVG 08816

MEDA PHARMA B.V.

NL

not available

10557

MEDA AS

DK

not available

10262

MEDA AS

DK

not available

BE128502

LABORATOIRES SMB S.A.

BE

not available

BE 128502

LABORATOIRES SMB S.A.

BE

not available

BE 128502

LABORATOIRES SMB S.A.

BE

not available

0160/99/01/4904

LABORATOIRES SMB S.A.

LU

not available

0160/99/01/4904

LABORATOIRES SMB S.A.

LU

tabletten met gereguleerde afgifte 250 mg Theolair Retard 350, tabletten met gereguleerde afgifte 350 mg Nuelin Retard, depottabletter Nuelin Retard, depottabletter PEDIAPHYLLIN 200 mg Comprimé à libération prolongée PEDIAPHYLLIN 200 mg, tablet met verlengde afgifte PEDIAPHYLLIN 200 mg Retardtablette PEDIAPHYLLIN 200 mg Comprimé à libération prolongée PEDIAPHYLLIN 200 mg Retardtablette

List of nationally authorised medicinal products EMA/135395/2018

Page 6/22

Product Name (in authorisation country)

MRP/DCP Authorisation number

National Authorisation Number

MAH of product in the member state

Member State where product is authorised

Xanthium 200 mg Gélules

not available

BE138573

LABORATOIRES SMB S.A.

BE

not available

BE158365

LABORATOIRES SMB S.A.

BE

not available

BE158365

LABORATOIRES SMB S.A.

BE

not available

BE138573

LABORATOIRES SMB S.A.

BE

not available

BE138564

LABORATOIRES SMB S.A.

BE

not available

BE138564

LABORATOIRES SMB S.A.

BE

not available

BE158365

LABORATOIRES SMB S.A.

BE

not available

BE138573

LABORATOIRES SMB S.A.

BE

not available

BE138564

LABORATOIRES SMB S.A.

BE

à libération prolongée Xanthium 300 mg Gélules à libération prolongée Xanthium 300 mg Capsule met verlengde afgifte, hard Xanthium 200 mg Hartkapseln, retardiert Xanthium 400 mg Gélules à libération prolongée Xanthium 400 mg Hartkapseln, retardiert Xanthium 300 mg Hartkapseln, retardiert Xanthium 200 mg Capsule met verlengde afgifte, hard Xanthium 400 mg Capsule met verlengde afgifte, hard

List of nationally authorised medicinal products EMA/135395/2018

Page 7/22

Product Name (in authorisation country)

MRP/DCP Authorisation number

National Authorisation Number

MAH of product in the member state

Member State where product is authorised

Xanthium 200 mg Gélules

not available

2002116791

LABORATOIRES SMB S.A.

LU

not available

2002116791

LABORATOIRES SMB S.A.

LU

not available

2002116792

LABORATOIRES SMB S.A.

LU

not available

2002116792

LABORATOIRES SMB S.A.

LU

not available

2002116793

LABORATOIRES SMB S.A.

LU

not available

2002116793

LABORATOIRES SMB S.A.

LU

not available

NL13804-3400932787821

SOCIETE D'ETUDES ET DE

FR

à libération prolongée Xanthium 200 mg Hartkapseln, retardiert Xanthium 300 mg Gélules à libération prolongée Xanthium 300 mg Hartkapseln, retardiert Xanthium 400 mg Gélules à libération prolongée Xanthium 400 mg Hartkapseln, retardiert DILATRANE 50 mg, gélule à libération prolongée

RECHERCHES PHARMACEUTIQUES (SERP)

Theo-Dur 300 mg

not available

9446

BIOPHAUSIA AB

SE

not available

9445

BIOPHAUSIA AB

SE

depottabletter Theo-Dur 200 mg depottabletter

List of nationally authorised medicinal products EMA/135395/2018

Page 8/22

Product Name (in authorisation country)

MRP/DCP Authorisation number

National Authorisation Number

MAH of product in the member state

Member State where product is authorised

UNIPHYLLIN® Ελιξίριο

not available

8570/06.02.2007

UNI-PHARMA KLEON TSETIS

GR

50mg/5ml

PHARMACEUTICAL LABORATORIES S.A.

UNIPHYLLIN® Σιρόπι

not available

8570/06.02.2007

50mg/5ml

UNI-PHARMA KLEON TSETIS

GR

PHARMACEUTICAL LABORATORIES S.A.

UNIPHYLLIN® Δισκία

not available

8570/06.02.2007

βραδείας αποδέσμευσης 100mg/tab UNIPHYLLIN® Δισκία

UNI-PHARMA KLEON TSETIS LABORATORIES S.A.

not available

8570/06.02.2007

UNI-PHARMA KLEON TSETIS

βραδείας αποδέσμευσης

PHARMACEUTICAL

200mg/tab

LABORATORIES S.A.

UNIPHYLLIN® Δισκία

not available

8570/06.02.2007

UNI-PHARMA KLEON TSETIS

βραδείας αποδέσμευσης

PHARMACEUTICAL

300mg/tab

LABORATORIES S.A.

UNIPHYLLIN® Κάψουλες

not available

8570/06.02.2007

UNI-PHARMA KLEON TSETIS

βραδείας αποδέσμευσης

PHARMACEUTICAL

100mg/cap

LABORATORIES S.A.

UNIPHYLLIN Κάψουλες

not available

8570/06.02.2007

βραδείας αποδέσμευσης

UNI-PHARMA KLEON TSETIS

GR

GR

GR

GR

PHARMACEUTICAL

350mg/cap UNIPHYLLIN® Υπόθετα

GR

PHARMACEUTICAL

LABORATORIES S.A. not available

8570/06.02.2007

100mg/supp

UNI-PHARMA KLEON TSETIS

GR

PHARMACEUTICAL LABORATORIES S.A.

UNIPHYLLIN® Υπόθετα

not available

350mg/supp

8570/06.02.2007

UNI-PHARMA KLEON TSETIS

GR

PHARMACEUTICAL LABORATORIES S.A.

List of nationally authorised medicinal products EMA/135395/2018

Page 9/22

Product Name (in authorisation country)

MRP/DCP Authorisation number

National Authorisation Number

MAH of product in the member state

Member State where product is authorised

UNIPHYLLIN, Eνέσιμο

not available

8570/06.02.2007

UNI-PHARMA KLEON TSETIS

GR

διάλυμα 240(218)mg/4ml

PHARMACEUTICAL

Amp

LABORATORIES S.A.

DILATRANE 200 mg,

not available

V07672-3400930317686

SOCIETE D'ETUDES ET DE

gélule à libération

RECHERCHES

prolongée

PHARMACEUTIQUES (SERP)

TEDRALAN 200 mg,

not available

VNL6671-3400931035398

gélule à libération

SOCIETE D'ETUDES ET DE

FR

FR

RECHERCHES

prolongée

PHARMACEUTIQUES (SERP)

Theo-Dur, depottabletter

not available

10044

BIOPHAUSIA AB

DK

Theo-Dur, depottabletter

not available

10045

BIOPHAUSIA AB

DK

Euphyllin long, 300 mg,

not available

4502

ASTRAZENECA AB

PL

not available

14/0135/94-S

ASTRAZENECA AB

SK

not available

4501

ASTRAZENECA AB

PL

not available

14/0003/13-S

ASTRAZENECA AB

SK

kapsulki o zmodyfikowanym uwalnianiu, twarde EUPHYLLIN CR N 200 kapsuly s predĺženým uvoľňovaním Euphyllin long, 200 mg, kapsułki o zmodyfikowanym uwalnianiu, twarde EUPHYLLIN CR N 300 kapsuly s predĺženým uvoľňovaním List of nationally authorised medicinal products EMA/135395/2018

Page 10/22

Product Name (in authorisation country)

MRP/DCP Authorisation number

National Authorisation Number

MAH of product in the member state

Member State where product is authorised

EUPHYLLIN CR N 400

not available

14/0004/13-S

ASTRAZENECA AB

SK

not available

14/078/99-C

ASTRAZENECA AB

CZ

not available

14/079/99-C

ASTRAZENECA AB

CZ

not available

14/080/99-C

ASTRAZENECA AB

CZ

not available

14/081/99-C

ASTRAZENECA AB

CZ

not available

025267016

RECORDATI INDUSTRIA

IT

kapsuly s predĺženým uvoľňovaním Euphyllin CR N 100 Tvrdá tobolka s prodlouženým uvolňováním Euphyllin CR N 200 Tvrdá tobolka s prodlouženým uvolňováním Euphyllin CR N 300 Tvrdá tobolka s prodlouženým uvolňováním Euphyllin CR N 400 Tvrdá tobolka s prodlouženým uvolňováním Theo-dur 300 mg compresse a rilascio

CHIMICA E FARMACEUTICA

prolungato

S.P.A.

Theo-dur 200 mg

not available

025267028

compresse a rilascio

RECORDATI INDUSTRIA

IT

CHIMICA E FARMACEUTICA

prolungato

S.P.A.

THEO-DUR®

not available

42686/09/12-2-2010

LAVIPHARM S.A

GR

THEO-DUR®

not available

42687/09/12-2-2010

LAVIPHARM S.A

GR

List of nationally authorised medicinal products EMA/135395/2018

Page 11/22

Product Name (in authorisation country)

MRP/DCP Authorisation number

National Authorisation Number

MAH of product in the member state

Member State where product is authorised

THEO-DUR®

not available

20100

LAVIPHARM LIMITED

CY

THEO-DUR®

not available

20099

LAVIPHARM LIMITED

CY

DILATRANE 300 mg,

not available

NL13805-3400932787999

SOCIETE D'ETUDES ET DE

FR

gélule à libération

RECHERCHES

prolongée

PHARMACEUTIQUES (SERP)

DIFFUMAL

not available

025740085

MALESCI ISTITUTO

IT

FARMACOBIOLOGICO S.P.A. DIFFUMAL

not available

025740097

MALESCI ISTITUTO

IT

FARMACOBIOLOGICO S.P.A. AMINOMAL 0,67%

not available

011226091

MALESCI ISTITUTO

soluzione orale (67

FARMACOBIOLOGICO -

mg/10 ml)

S.P.A.

AFONILUM SR 125 125

IT

not available

14/0595/94-S

BGP PRODUCTS S.R.O.

SK

not available

14/0595/94-S

BGP PRODUCTS S.R.O.

SK

not available

14/0595/94-S

BGP PRODUCTS S.R.O.

SK

mg, kapsuly s predlženým uvolnovaním AFONILUM SR 250 250 mg, kapsuly s predlženým uvolnovaním AFONILUM SR 375 375mg|kapsuly s predlženým uvolnovaním

List of nationally authorised medicinal products EMA/135395/2018

Page 12/22

Product Name (in authorisation country)

MRP/DCP Authorisation number

National Authorisation Number

MAH of product in the member state

Member State where product is authorised

THEOSTAT 100 mg A

not available

326 913-9

PIERRE FABRE MEDICAMENT

FR

not available

327 873.0

SAS PIERRE FABRE

FR

LIBERATION PROLONGEE, comprimé sécable THEOSTAT LP 200 mg, comprimé sécable à

MEDICAMENT

libération prolongée THEOSTAT 300 mg A

not available

34009 326 021 0 0

PIERRE FABRE MEDICAMENT

FR

not available

327 874.7

PIERRE FABRE MEDICAMENT

FR

not available

327 875.3

PIERRE FABRE MEDICAMENT

FR

not available

327 877.6

PIERRE FABRE MEDICAMENT

FR

not available

554 929.7

PIERRE FABRE MEDICAMENT

FR

not available

326 914-5

PIERRE FABRE MEDICAMENT

FR

LIBERATION PROLONGEE, comprimé sécable THEOSTAT LP 200 mg, comprimé sécable à libération prolongée THEOSTAT LP 200 mg, comprimé sécable à libération prolongée THEOSTAT LP 200 mg, comprimé sécable à libération prolongée THEOSTAT LP 200 mg, comprimé sécable à libération prolongée THEOSTAT 100 mg A LIBERATION PROLONGEE, comprimé sécable

List of nationally authorised medicinal products EMA/135395/2018

Page 13/22

Product Name (in authorisation country)

MRP/DCP Authorisation number

National Authorisation Number

MAH of product in the member state

Member State where product is authorised

THEOSTAT 100 mg A

not available

326 915-1

PIERRE FABRE MEDICAMENT

FR

not available

327 138-9

PIERRE FABRE MEDICAMENT

FR

not available

554 701-6

PIERRE FABRE MEDICAMENT

FR

not available

556 814-2

PIERRE FABRE MEDICAMENT

FR

not available

34009 327 314 1 1

PIERRE FABRE MEDICAMENT

FR

not available

34009 554 187 0 2

PIERRE FABRE MEDICAMENT

FR

not available

14/900//92-C

PIERRE FABRE MEDICAMENT

CZ

LIBERATION PROLONGEE, comprimé sécable THEOSTAT 100 mg A LIBERATION PROLONGEE, comprimé sécable THEOSTAT 100 mg A LIBERATION PROLONGEE, comprimé sécable THEOSTAT 100 mg A LIBERATION PROLONGEE, comprimé sécable THEOSTAT 300 mg A LIBERATION PROLONGEE, comprimé sécable THEOSTAT 300 mg A LIBERATION PROLONGEE, comprimé sécable THEOPLUS 100 Tableta s prodlouženým uvolňováním

List of nationally authorised medicinal products EMA/135395/2018

Page 14/22

Product Name (in authorisation country)

MRP/DCP Authorisation number

National Authorisation Number

MAH of product in the member state

Member State where product is authorised

THEOPLUS 100

not available

14/0900/92-S

SAS PIERRE FABRE

SK

MEDICAMENT THEOPLUS 300 Tableta s

not available

14/900/92- A/C

PIERRE FABRE MEDICAMENT

CZ

THEOPLUS 300

not available

14/900/92-S

PIERRE FABRE MEDICAMENT

SK

Theophyllin STADA® 200

not available

33294.01.00

STADAPHARM GMBH

DE

not available

33294.02.00

STADAPHARM GMBH

DE

not available

BE128502

LABORATOIRES SMB S.A.

BE

not available

BE 128502

LABORATOIRES SMB S.A.

BE

not available

BE 128502

LABORATOIRES SMB S.A.

BE

not available

0160/99/01/4904

LABORATOIRES SMB S.A.

LU

prodlouženým uvolňováním

mg Hartkapseln, retardiert Theophyllin STADA® 300 mg Hartkapseln, retardiert PEDIAPHYLLIN 200 mg Comprimé à libération prolongée PEDIAPHYLLIN 200 mg, tablet met verlengde afgifte PEDIAPHYLLIN 200 mg Retardtablette PEDIAPHYLLIN 200 mg Comprimé à libération prolongée

List of nationally authorised medicinal products EMA/135395/2018

Page 15/22

Product Name (in authorisation country)

MRP/DCP Authorisation number

National Authorisation Number

MAH of product in the member state

Member State where product is authorised

PEDIAPHYLLIN 200 mg

not available

0160/99/01/4904

LABORATOIRES SMB S.A.

LU

not available

BE138573

LABORATOIRES SMB S.A.

BE

not available

BE158365

LABORATOIRES SMB S.A.

BE

not available

BE158365

LABORATOIRES SMB S.A.

BE

not available

BE138573

LABORATOIRES SMB S.A.

BE

not available

BE138564

LABORATOIRES SMB S.A.

BE

not available

BE138564

LABORATOIRES SMB S.A.

BE

not available

BE158365

LABORATOIRES SMB S.A.

BE

not available

BE138573

LABORATOIRES SMB S.A.

BE

Retardtablette Xanthium 200 mg Gélules à libération prolongée Xanthium 300 mg Gélules à libération prolongée Xanthium 300 mg Capsule met verlengde afgifte, hard Xanthium 200 mg Hartkapseln, retardiert Xanthium 400 mg Gélules à libération prolongée Xanthium 400 mg Hartkapseln, retardiert Xanthium 300 mg Hartkapseln, retardiert Xanthium 200 mg Capsule met verlengde afgifte, hard

List of nationally authorised medicinal products EMA/135395/2018

Page 16/22

Product Name (in authorisation country)

MRP/DCP Authorisation number

National Authorisation Number

MAH of product in the member state

Member State where product is authorised

Xanthium 400 mg

not available

BE138564

LABORATOIRES SMB S.A.

BE

not available

2002116791

LABORATOIRES SMB S.A.

LU

not available

2002116791

LABORATOIRES SMB S.A.

LU

not available

2002116792

LABORATOIRES SMB S.A.

LU

not available

2002116792

LABORATOIRES SMB S.A.

LU

not available

2002116793

LABORATOIRES SMB S.A.

LU

not available

2002116793

LABORATOIRES SMB S.A.

LU

not available

21810.00.01

TAKEDA GMBH (KONSTANZ)

DE

not available

3003022.01.00

TAKEDA GMBH (KONSTANZ)

DE

Capsule met verlengde afgifte, hard Xanthium 200 mg Gélules à libération prolongée Xanthium 200 mg Hartkapseln, retardiert Xanthium 300 mg Gélules à libération prolongée Xanthium 300 mg Hartkapseln, retardiert Xanthium 400 mg Gélules à libération prolongée Xanthium 400 mg Hartkapseln, retardiert Euphylong® i.v. 200, 200 mg, Injektionslösung Euphylong® 200 mg, Hartkapsel, retardiert

List of nationally authorised medicinal products EMA/135395/2018

Page 17/22

Product Name (in authorisation country)

MRP/DCP Authorisation number

National Authorisation Number

MAH of product in the member state

Member State where product is authorised

Euphylong® 250 mg,

not available

9689.00.00

TAKEDA GMBH (KONSTANZ)

DE

not available

027435078

TAKEDA ITALIA S.P.A.

IT

not available

24676.02.00

TAKEDA GMBH (KONSTANZ)

DE

not available

027435080

TAKEDA ITALIA S.P.A.

IT

not available

3003022.00.00

TAKEDA GMBH (KONSTANZ)

DE

not available

34009 338 494 6 7

TAKEDA FRANCE S.A.S.

FR

not available

R/6654

TAKEDA PHARMA SP.Z.O.O.

PL

not available

027435155

TAKEDA ITALIA S.P.A.

IT

not available

34009 333 752 7 0

TAKEDA FRANCE S.A.S.

FR

Hartkapsel, retardiert Respicur 400 mg capsule rigide a rilascio prolungato Euphylong® 125 mg, Hartkapsel, retardiert Respicur 200 mg capsule rigide a rilascio prolungato Euphylong® 300 mg, Hartkapsel, retardiert EUPHYLLINE L.A. 400 mg, gélule à libération prolongée Euphyllin CR retard, 250 mg, tabletki o przedłużonym uwalnianiu Respicur 300 mg capsule rigide a rilascio prolungato EUPHYLLINE L.A. 100 mg, gélule à libération prolongée

List of nationally authorised medicinal products EMA/135395/2018

Page 18/22

Product Name (in authorisation country)

MRP/DCP Authorisation number

National Authorisation Number

MAH of product in the member state

Member State where product is authorised

EUPHYLLINE L.A. 300

not available

34009 333 753 3 1

TAKEDA FRANCE S.A.S.

FR

not available

34009 555 162 1 7

TAKEDA FRANCE S.A.S.

FR

not available

34009 553 061 3 9

TAKEDA FRANCE S.A.S.

FR

not available

34009 325 016 3 2

TAKEDA FRANCE S.A.S.

FR

not available

34009 560 449 3 1

TAKEDA FRANCE S.A.S.

FR

not available

34009 333 751 0 2

TAKEDA FRANCE S.A.S.

FR

not available

34009 560 452 4 2

TAKEDA FRANCE S.A.S.

FR

not available

34009 328 014 1 1

TAKEDA FRANCE S.A.S.

FR

not available

34009 325 018 6 1

TAKEDA FRANCE S.A.S.

FR

mg, gélule à libération prolongée EUPHYLLINE L.A. 200 mg, gélule à libération prolongée EUPHYLLINE L.A. 100 mg, gélule à libération prolongée EUPHYLLINE L.A. 100 mg, gélule à libération prolongée EUPHYLLINE L.A. 100 mg, gélule à libération prolongée EUPHYLLINE L.A. 200 mg, gélule à libération prolongée EUPHYLLINE L.A. 200 mg, gélule à libération prolongée EUPHYLLINE L.A. 200 mg, gélule à libération prolongée EUPHYLLINE L.A. 300 mg, gélule à libération prolongée

List of nationally authorised medicinal products EMA/135395/2018

Page 19/22

Product Name (in authorisation country)

MRP/DCP Authorisation number

National Authorisation Number

MAH of product in the member state

Member State where product is authorised

EUPHYLLINE L.A. 300

not available

34009 560 450 1 3

TAKEDA FRANCE S.A.S.

FR

not available

34009 553 063 6 8

TAKEDA FRANCE S.A.S.

FR

not available

34009 560 451 8 1

TAKEDA FRANCE S.A.S.

FR

not available

34009 555 168 8 5

TAKEDA FRANCE S.A.S.

FR

not available

34009 328 218 6 0

TAKEDA FRANCE S.A.S.

FR

not available

14/468/95-A/C

BGP PRODUCTS CZECH

CZ

mg, gélule à libération prolongée EUPHYLLINE L.A. 300 mg, gélule à libération prolongée EUPHYLLINE L.A. 400 mg, gélule à libération prolongée EUPHYLLINE L.A. 400 mg, gélule à libération prolongée EUPHYLLINE L.A. 400 mg, gélule à libération prolongée Afonilum SR 125 mg Tvrdá tobolka s

REPUBLIC S.R.O.

prodlouženým uvolňováním Afonilum SR 250 mg

not available

14/468/95-B/C

Tvrdá tobolka s

BGP PRODUCTS CZECH

CZ

REPUBLIC S.R.O.

prodlouženým uvolňováním Uniphyllin® 300 mg

not available

25497.00.00

MUNDIPHARMA GMBH

DE

Uniphyllin® 400 mg

not available

02738.00.00

MUNDIPHARMA GMBH

DE

List of nationally authorised medicinal products EMA/135395/2018

Page 20/22

Product Name (in authorisation country)

MRP/DCP Authorisation number

National Authorisation Number

MAH of product in the member state

Member State where product is authorised

Uniphyllin® 600 mg

not available

02738.02.00

MUNDIPHARMA GMBH

DE

Unifyl retard 300 mg

not available

1-18815

MUNDIPHARMA GES.M.B.H

AT

not available

1-18171

MUNDIPHARMA GES.M.B.H

AT

not available

1-17835

MUNDIPHARMA GES.M.B.H

AT

not available

1-18818

MUNDIPHARMA GES.M.B.H

AT

not available

19865

MUNDIPHARMA

CY

Tabletten Unifyl retard 200 mg Tabletten Unifyl retard 400 mg Tabletten Unifyl retard 600 mg Tabletten UNIPHYLLIN CONTINUS tablets 400 mg UNIPHYLLIN®

PHARMACEUTICALS LTD not available

PA 1688/11/1

CONTINUS® 200 mg

MUNDIPHARMA

IE

PHARMACEUTICALS LIMITED

prolonged release tablets UNIPHYLLIN®

not available

PA 1688/11/2

CONTINUS® 300 mg

MUNDIPHARMA

IE

PHARMACEUTICALS LIMITED

prolonged release tablets UNIPHYLLIN®

not available

CONTINUS® 400 mg

PA 1688/11/3

MUNDIPHARMA

IE

PHARMACEUTICALS LIMITED

prolonged release tablets

List of nationally authorised medicinal products EMA/135395/2018

Page 21/22

Product Name (in authorisation country)

MRP/DCP Authorisation number

National Authorisation Number

MAH of product in the member state

Member State where product is authorised

UNIPHYLLIN CONTINUS

not available

PL 16950/0066

NAPP PHARMACEUTICALS

UK

200 mg prolonged

LTD

release tablets UNIPHYLLIN CONTINUS

not available

PL 16950/0067

300 mg prolonged

NAPP PHARMACEUTICALS

UK

LTD

release tablets UNIPHYLLIN CONTINUS

not available

PL 16950/0068

400 mg prolonged

NAPP PHARMACEUTICALS

UK

LTD

release tablets Unicontin 400 mg

not available

9628719

comprimidos de

MEDA PHARMA – PRODUTOS

PT

FARMACÊUTICOS, S.A.

libertação prolongada Unicontin 400 mg

not available

comprimidos de

9628727

MEDA PHARMA – PRODUTOS

PT

FARMACÊUTICOS, S.A.

libertação prolongada

List of nationally authorised medicinal products EMA/135395/2018

Page 22/22

PSUSA/00002921/201706 - European Medicines Agency - Europa EU

Mar 8, 2018 - Theophyllin STADA® 400 mg Hartkapseln, retardiert not available. 31200.00.00. STADAPHARM GMBH. DE. Slo-Phyllin 125 mg. Capsules not available. PL 11648/0080. MERCK SERONO LTD. UK. Slo-Phyllin 250 mg. Capsules not available. PL 11648/0081. MERCK SERONO LTD. UK. Slo-Phyllin 60 mg.

190KB Sizes 6 Downloads 291 Views

Recommend Documents

Agenda - European Medicines Agency - Europa EU
Jul 7, 2017 - COMMUNITY MARKETING AUTHORISATIONS AND EXTENSIONS. 2.1. Opinions ... Quality. Rapp: E. Werner .... solutions table with EMA and CVMP responses to the recommendations made by the FishMed Plus. Coalition ...

May 2016 - European Medicines Agency - Europa EU
Jun 22, 2016 - Information Management Division ... This document provides current information related to the volume and evaluation of .... Plasma master file.

Eleclazine - European Medicines Agency - Europa EU
Feb 9, 2017 - Notification of discontinuation of a paediatric development which is covered by an agreed ... for the following reason(s): (tick all that apply).

July 2017 - European Medicines Agency - Europa EU
Jul 5, 2017 - Send a question via our website www.ema.europa.eu/contact ... non-proprietary names (INN) and therapeutic areas for all new ... also available in the monthly reports of the Committee for Orphan Medicinal Products (COMP).

July 2016 - European Medicines Agency - Europa EU
Jul 4, 2016 - Send a question via our website www.ema.europa.eu/contact ... non-proprietary names (INN) and therapeutic areas for all new ... also available in the monthly reports of the Committee for Orphan Medicinal Products (COMP).

SME Office - European Medicines Agency - Europa EU
maximises the chances of a successful marketing authorisation. ... marketing authorisation. • inclusion in the public SME ... E-mail [email protected]. Website ...

Agenda - European Medicines Agency - Europa EU
Jun 19, 2017 - and may also vary during the course of the review. ...... ViiV Healthcare UK Limited; Treatment of Human Immunodeficiency Virus ..... adjunctive administration of brivaracetam, Treatment of paediatric patients with partial.

Action plan - European Medicines Agency - Europa EU
5 days ago - Guidelines should include more details on the principles of good information design in which content and layout are ... relevance and importance of the QRD template is also acknowledged in this respect as it is the main tool .... databas

Agenda - European Medicines Agency - Europa EU
Jun 15, 2016 - Agenda - EMA Human Scientific Committees' Working. Parties with Healthcare Professionals' Organisations. (HCPWP) meeting. 15 June 2016, 08:45hrs to 10:30hrs – meeting room: 3E. Chairs: I. Moulon (EMA) and Gonzalo Calvo (HCPWP). 15 Ju

Agenda - European Medicines Agency - Europa EU
Jun 26, 2018 - oxadiazole-3-carboximidamide - EMEA-002072-PIP01-16-M01 . ..... Human alpha-galactosidase A - Orphan - EMEA-001828-PIP01-15-M01 .

Agenda - European Medicines Agency - Europa EU
Jul 16, 2018 - Cladribine, EMA/OD/087/17 Recombinant monoclonal antibody to sialic acid-binding Ig-like lectin 8. 2.2.6. - EMA/OD/098/18. Treatment of ...

SPOR - European Medicines Agency - Europa EU
Feb 7, 2017 - Add an existing Tag to a specific Term . ...... This service creates an email body (text/html) of a user's notification data, a notification is based on.

ATMP - European Medicines Agency - Europa EU
Nov 24, 2017 - E8. 09/08/2017. 10/08/2017. 24/08/2017 17/08/2017 22/08/2017. 24/08/2017. 30/08/2017. 01/09/2017. 04/09/2017. 08/09/2017. 14/09/2017.

Agenda - European Medicines Agency - Europa EU
Feb 9, 2018 - 30 Churchill Place ○ Canary Wharf ○ London E14 5EU ○ United Kingdom. An agency of the European Union ... product information. For information: Summary of opinion. 2.2. Oral explanations and list of outstanding issues. •. Product

Agenda - European Medicines Agency - Europa EU
Oct 23, 2017 - Page 2/61. Table of contents. 1. Introduction. 11. 1.1. Welcome and declarations of interest of members, alternates and experts .......... 11. 1.2. Agenda of the meeting on 23-26 October 2017 . ...... different database to study the ri

Evofosfamide - European Medicines Agency - Europa EU
Notification of discontinuation of a paediatric development which is covered by an agreed ... for the following reason(s): (tick all that apply). (possible) lack of ...

Agenda - European Medicines Agency - Europa EU
17 Jan 2018 - Expert meeting on adeno-associated viral vectors, 06 September 2017, EMA, London. CAT: Martina Schüßler-Lenz. Scope: report of the meeting that took place on 6 September 2017. Action: for adoption. 7.6.3. Environmental assessment of g

minoxidil - European Medicines Agency - Europa EU
Jun 14, 2018 - Page 2/26. Product Name (in authorisation country). MRP/DCP Authorisation number. National Authorisation. Number. MAH of product in the.

Influenza vaccine - European Medicines Agency - Europa EU
Oct 26, 2017 - Injektionssuspension in einer Fertigspritze. Influenza-Impfstoff. (Spaltimpfstoff, inaktiviert, in Zellkulturen hergestellt) not available. BE393556. NANOTHERAPEUTICS. BOHUMIL, S.R.O.. BE. Preflucel injektionsvätska, suspension i för

latanoprost - European Medicines Agency - Europa EU
May 13, 2016 - Send a question via our website www.ema.europa.eu/contact. © European ... Product Name (in authorisation ..... Xaloptic Free. NL/H/3193/001.

Cyproterone/ethinylestradiol - European Medicines Agency - Europa EU
March 2016 a joint database drug utilisation final study report to the European .... With regards to prescription of CPA/EE for contraceptive management, ...

ganciclovir - European Medicines Agency - Europa EU
Feb 9, 2017 - Send a question via our website www.ema.europa.eu/contact. © European ... Product Name (in authorisation ... not available. 20010180.

July 2016 - European Medicines Agency - Europa EU
For a list of RSS readers please refer to our RSS guide and follow the instructions ..... PCWP and HCPWP joint meeting: Workshop on social media - Sep 2016.

Stem cell - European Medicines Agency - Europa EU
Jul 14, 2016 - Stem cell-based products for veterinary use: specific ... potentially delay time to rejection providing a window of therapeutic benefit but limiting ...